# A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

> **NCT05895812** · PHASE1 · COMPLETED · sponsor: **Shanghai Vinnerna Biosciences Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Subjects With Renal Impairment
- Healthy Subjects

## Interventions

- **DRUG:** Deuremidevir Hydrobromide Tablets

## Key facts

- **NCT ID:** NCT05895812
- **Lead sponsor:** Shanghai Vinnerna Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-08
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-08-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895812, "A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05895812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*